Does the media prefer MLTX or XFOR?

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 5 mentions for X4 Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat X4 Pharmaceuticals' score of 0.17 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XFOR or MPLT?

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.60 beat X4 Pharmaceuticals' score of 0.17 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

X4 Pharmaceuticals (XFOR) Competitors

$4.13 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.13 0.00 (0.00%)

As of 07/2/2026 07:59 PM Eastern

Compare

XFOR vs. DMRA, MLTX, KALV, MPLT, and INBX

Should you buy X4 Pharmaceuticals stock or one of its competitors? MarketBeat compares X4 Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with X4 Pharmaceuticals include Damora Therapeutics, Inc. Common Stock (DMRA), MoonLake Immunotherapeutics (MLTX), KalVista Pharmaceuticals (KALV), Maplight Therapeutics (MPLT), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

How does X4 Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.43, suggesting a potential upside of 41.52%. X4 Pharmaceuticals has a consensus target price of $9.38, suggesting a potential upside of 127.00%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Damora Therapeutics, Inc. Common Stock. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

X4 Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
X4 Pharmaceuticals	$35.11M	11.09	-$79.20M	-$4.54	N/A

Summary

X4 Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 5 mentions for X4 Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.54 beat X4 Pharmaceuticals' score of 0.17 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. MoonLake Immunotherapeutics' return on equity of -85.15% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

X4 Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
X4 Pharmaceuticals	$35.11M	11.09	-$79.20M	-$4.54	N/A

MoonLake Immunotherapeutics presently has a consensus price target of $24.21, suggesting a potential upside of 27.78%. X4 Pharmaceuticals has a consensus price target of $9.38, suggesting a potential upside of 127.00%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

MoonLake Immunotherapeutics beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 0 mentions for KalVista Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.17 beat KalVista Pharmaceuticals' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
KalVista Pharmaceuticals	Neutral
X4 Pharmaceuticals	Neutral

KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

KalVista Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

KalVista Pharmaceuticals currently has a consensus target price of $30.60, suggesting a potential upside of 13.33%. X4 Pharmaceuticals has a consensus target price of $9.38, suggesting a potential upside of 127.00%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

X4 Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
X4 Pharmaceuticals	$35.11M	11.09	-$79.20M	-$4.54	N/A

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

X4 Pharmaceuticals beats KalVista Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Maplight Therapeutics?

X4 Pharmaceuticals (NASDAQ:XFOR) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

X4 Pharmaceuticals presently has a consensus price target of $9.38, indicating a potential upside of 127.00%. Maplight Therapeutics has a consensus price target of $38.80, indicating a potential upside of 4.61%. Given X4 Pharmaceuticals' higher probable upside, equities research analysts plainly believe X4 Pharmaceuticals is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.60 beat X4 Pharmaceuticals' score of 0.17 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Maplight Therapeutics' return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Maplight Therapeutics	N/A	N/A	N/A

X4 Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.09	-$79.20M	-$4.54	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Inhibrx Biosciences?

X4 Pharmaceuticals (NASDAQ:XFOR) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, X4 Pharmaceuticals had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 0 mentions for Inhibrx Biosciences. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Inhibrx Biosciences' score of -0.35 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
X4 Pharmaceuticals	Neutral
Inhibrx Biosciences	Neutral

X4 Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.09	-$79.20M	-$4.54	N/A
Inhibrx Biosciences	$1.30M	1,101.15	-$140.05M	-$8.39	N/A

Inhibrx Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

X4 Pharmaceuticals currently has a consensus target price of $9.38, indicating a potential upside of 127.00%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 53.72%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

X4 Pharmaceuticals has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, indicating that its share price is 241% more volatile than the broader market.

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

X4 Pharmaceuticals beats Inhibrx Biosciences on 11 of the 17 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XFOR vs. The Competition

Export

Metric	X4 Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$389.54M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.50%
P/E Ratio	-0.91	21.61	28.02	24.70
Price / Sales	11.09	325.90	532.59	97.92
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.94	8.66	10.96	6.46
Net Income	-$79.20M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.74%	3.39%	2.12%	1.69%
1 Month Performance	7.83%	10.81%	5.25%	3.81%
1 Year Performance	110.18%	62.61%	33.29%	23.90%

X4 Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XFOR X4 Pharmaceuticals	2.9005 of 5 stars	$4.13 flat	$9.38 +127.0%	+110.2%	$389.54M	$35.11M	N/A	80	News Coverage
DMRA Damora Therapeutics, Inc. Common Stock	3.0015 of 5 stars	$24.21 -4.5%	$42.43 +75.3%	+769.0%	$1.49B	N/A	N/A	40	Gap Down
MLTX MoonLake Immunotherapeutics	3.2427 of 5 stars	$19.91 +0.1%	$23.85 +19.8%	-59.1%	$1.46B	N/A	N/A	2	Analyst Forecast Insider Trade
KALV KalVista Pharmaceuticals	2.2534 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100
MPLT Maplight Therapeutics	2.0573 of 5 stars	$34.30 +3.1%	$38.80 +13.1%	N/A	$1.42B	N/A	N/A	109

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XFOR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. DMRA, MLTX, KALV, MPLT, and INBX

How does X4 Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does X4 Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does X4 Pharmaceuticals compare to KalVista Pharmaceuticals?

Summary

How does X4 Pharmaceuticals compare to Maplight Therapeutics?

Summary

How does X4 Pharmaceuticals compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. DMRA, MLTX, KALV, MPLT, and INBX

How does X4 Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Do insiders and institutionals hold more shares of DMRA or XFOR?

Which has more volatility & risk, DMRA or XFOR?

Do analysts recommend DMRA or XFOR?

Does the media prefer DMRA or XFOR?

Is DMRA or XFOR more profitable?

Which has better valuation & earnings, DMRA or XFOR?

Summary

How does X4 Pharmaceuticals compare to MoonLake Immunotherapeutics?

Does the media prefer MLTX or XFOR?

Do institutionals & insiders hold more shares of MLTX or XFOR?

Which has more volatility and risk, MLTX or XFOR?

Is MLTX or XFOR more profitable?

Which has higher valuation and earnings, MLTX or XFOR?

Do analysts recommend MLTX or XFOR?

Summary

How does X4 Pharmaceuticals compare to KalVista Pharmaceuticals?

Does the media favor KALV or XFOR?

Which has more risk & volatility, KALV or XFOR?

Is KALV or XFOR more profitable?

Do analysts recommend KALV or XFOR?

Which has preferable earnings & valuation, KALV or XFOR?

Do institutionals and insiders hold more shares of KALV or XFOR?

Summary

How does X4 Pharmaceuticals compare to Maplight Therapeutics?

Do analysts rate XFOR or MPLT?

Do insiders and institutionals hold more shares of XFOR or MPLT?

Does the media prefer XFOR or MPLT?

Is XFOR or MPLT more profitable?

Which has better valuation and earnings, XFOR or MPLT?

Summary

How does X4 Pharmaceuticals compare to Inhibrx Biosciences?

Does the media refer more to XFOR or INBX?

Which has higher earnings & valuation, XFOR or INBX?

Is XFOR or INBX more profitable?

Do analysts rate XFOR or INBX?

Which has more volatility & risk, XFOR or INBX?

Do insiders & institutionals hold more shares of XFOR or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools